Despite treatment advances, MM is not curable and while current ... including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be ...

Despite treatment advances, MM is not curable and while current ... including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be ...

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

Also helping compensate for the sales decline of Xarelto was a strong performance by Eylea, which was up 4%, thanks to the launch of the longer-acting version of the eye disease treatment.

May 23, 2025 Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals ...

Eylea, mainly used to treat various eye conditions, has also seen sales increase, while Bayer’s radiology business has been strong too. Similarly, contraceptive drugs such as YAZ and Mirena have ...

Additionally, sales for opthalmology drug Eylea ... treatment. Additionally, generic competition can also pressure growth and margins. The acquisition of Monsanto has significantly expanded Bayer ...

The launch of Eylea 8 mg, offering longer treatment intervals, provided a boost to sales, especially in Japan and the EU. Please note that Bayer’s HealthCare unit co-develops Eylea with ...